DeciBio conducted 11 interviews with KOLs at pharmaceutical companies to understand how pharma spends their money in support of therapeutic / precision medicine development initiatives today, and how these investments may change in the future. Sample areas explored include research tools, informatics, companion diagnostics, clinical trial operations, laboratory automation, and more. Experts additionally elaborated on which areas have yielded the greatest vs least perceived ROI, whether that be helping to improve patient care pathways, cutting down developmental timelines, or some other metric entirely.

Over the course of the discussion, stakeholders were asked to score their levels of investment across these different investment categories, providing clear cashflow trends. In addition to describing the underlying organizational drivers of investment, stakeholders outlined other macro trends (e.g., regulation requirements, broader usage of companion diagnostics) that may impact their decisions in the future.

This report is organized around the responses to 9 key study questions

• What are the primary objectives your organization seeks to achieve when making investments into drug development?
• Over the last 3 – 5 years, what was your organization’s relative investment in each of these areas?
• Within research tools, what has been the relative investment across different modalities at your organization over the last 3 – 5 years?
• Which investments do you perceive as yielding the greatest ROI?
• Which investments do you perceive as yielding the least, or lower-than-expected ROI?
• In which areas do you expect your organization’s relative level of investment to materially increase or decrease in the next 3 – 5 years?
• What pain points exist for pharma today?
• What key trends do you expect will have the most significant impact on oncology in the next 3 – 5 years?
• What events may impact oncology, and what trends in oncology may impact other disease areas?

Investment Categories Discussed

• Research Tools
• Informatics
• Clinical Trial Operations Solutions
• Companion Diagnostics
• In-Vitro Modeling
• Specimen Acquisition
• Real World Data
• Laboratory Automation
• Supply Chain Solutions

This advisory board is meant to be a qualitative, limited scope study, and the intent is to highlight the unbiased and unfiltered feedback just from the stakeholders interviewed, not provide a comprehensive market assessment. DeciBio also has a suite of comprehensive market reports (Link Here) if broader industry level insights are of interest. 

‍